NCT04868292View on ClinicalTrials.gov

Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

34

Participants

Timeline

Start Date

June 3, 2021

Primary Completion Date

September 16, 2021

Study Completion Date

September 29, 2021

Conditions

Healthy Volunteers

Interventions

DRUG

SPR206

Three 100 mg SPR206 intravenous doses administered every 8 hours

Trial Locations (1)

M23 9QZ

Medical Facility, Manchester

Sponsors

Lead Sponsor

Spero Therapeutics

All Listed Sponsors

collaborator

United States Department of Defense

FED

lead

Spero Therapeutics

INDUSTRY

NCT04868292 - Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunteers | Biotech Hunter | Biotech Hunter